Recent News

• 03.10.2025 - Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery
• 02.24.2025 - IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel
• 02.10.2025 - IceCure to Exhibit at the St. Gallen Breast Cancer Conference 2025
• 02.04.2025 - IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision
• 01.27.2025 - IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China
• 01.13.2025 - IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America
• 01.06.2025 - IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule
• 01.06.2025 - IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

Recent Filings

• 03.10.2025 - EX-99.1 EX-99.1
• 03.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.24.2025 - EX-99.1 EX-99.1
• 02.04.2025 - EX-99.1 EX-99.1
• 02.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.13.2025 - 424B5 Prospectus [Rule 424(b)(5)]